2026-04-14T06:24:53Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1599172025-11-19T11:04:15Zcom_2072_1057col_2072_478917col_2072_478924

00925njm 22002777a 4500 dc González-Domínguez, Raúl author Sayago, Ana author Fernández-Recamales, Ángeles author 2020-05-13T07:15:23Z 2020-05-13T07:15:23Z 2017-12-15 2020-05-13T07:15:23Z Alzheimer's disease is a complex neurodegenerative disorder characterized by a multi-factorial etiology, not completely understood to date. In this context, the application of metabolomics is emerging in the last years because of its potential to monitor molecular alterations associated with disease pathogenesis and progression, as well as to discover candidate diagnostic biomarkers. However, the huge heterogeneity and dynamism of the human metabolome makes impossible the simultaneous determination of the entire set of metabolites from complex biological samples. Thus, the most common strategy to get a comprehensive overview of the organism's phenotypic expression is the combined use of complementary metabolomic platforms. In this review, we summarize the advantages and limitations of the most important analytical techniques usually employed in metabolomics, including nuclear magnetic resonance, direct infusion mass spectrometry and hyphenated approaches based on the coupling of orthogonal separation mechanisms (i.e. liquid chromatography, gas chromatography, capillary electrophoresis) with mass spectrometry. Moreover, the suitability of metabolomics to unravel the complex pathology underlying to Alzheimer's disease is also presented. (C) 2017 Elsevier B.V. All rights reserved. Malaltia d'Alzheimer Metabolòmica Espectrometria de masses Ressonància magnètica nuclear Alzheimer's disease Metabolomics Mass spectrometry Nuclear magnetic resonance Metabolomics in Alzheimer's disease: The need of complementary analytical platforms for the identification of biomarkers to unravel the underlying pathology